Intellia Therapeutics (NTLA) Tops Q3 EPS by 12c

Intellia Therapeutics (NASDAQ: NTLA) reported Q3 EPS of ($1.38), $0.12 better than the analyst estimate of ($1.50). Revenue for the quarter came in at $12 million versus the consensus estimate of $12.45 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.

You May Also Be Interested In

• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
• RUM Group to raise Northern Data stake to ~98% via share purchase
• RH shares jump after second quarter beat